Evidence map›Paper›PMID 32873509›Full record

ArticleCytotherapy2020

Identification and characterization of a large source of primary mesenchymal stem cells tightly adhered to bone surfaces of human vertebral body marrow cavities.

Brian H Johnstone, Hannah M Miller, Madelyn R Beck, Dongsheng Gu, Sreedhar Thirumala, Michael LaFontaine, Gerald Brandacher, Erik J Woods

Open access · hybridAbstract read
In one paragraph

Article in Cytotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Brian H JohnstoneOssium Health, Inc, Indianapolis, Indiana, USA; Department of Biomedical Sciences, College of Osteopathic Medicine, Marian University, Indianapolis, Indiana, USA. Electronic address: brian.johnstone@ossiumhealth.com.
Hannah M MillerOssium Health, Inc, Indianapolis, Indiana, USA; Department of Biomedical Sciences, College of Osteopathic Medicine, Marian University, Indianapolis, Indiana, USA.
Madelyn R BeckDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Dongsheng GuOssium Health, Inc, Indianapolis, Indiana, USA; Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Sreedhar ThirumalaDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Michael LaFontaineDepartment of Biomedical Sciences, College of Osteopathic Medicine, Marian University, Indianapolis, Indiana, USA.
Gerald BrandacherDepartment of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Erik J WoodsOssium Health, Inc, Indianapolis, Indiana, USA; Department of Biomedical Sciences, College of Osteopathic Medicine, Marian University, Indianapolis, Indiana, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Electronic address: erik@ossiumhealth.com.
Marian University - Indiana · USIndiana University School of MedicineIndiana University – Purdue University Indianapolis · USJohns Hopkins Medicine · US

Funding

OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.U01AI138334 · NIAID · OSSIUM HEALTH, INC. · PI WOODS, ERIK J. · 2018 to 2022
$3.0M
Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone MarrowR44AI129444 · NIAID · OSSIUM HEALTH, INC. · PI WOODS, ERIK J. · 2019 to 2020
$1.7M
Novel strategies for storage and recovery of cadaveric bone marrow stem cellsR44HL142418 · NHLBI · OSSIUM HEALTH, INC. · PI WOODS, ERIK J. · 2020 to 2021
$1.5M
Deceased Donor Bone Marrow Salvage and ProcessingR43AI129444 · NIAID · OSSIUM HEALTH, INC. · PI WOODS, ERIK J. · 2017 to 2017
$273k
Novel strategies for storage and recovery of cadaveric bone marrow stem cellsR43HL142418 · NHLBI · OSSIUM HEALTH, INC. · PI WOODS, ERIK J. · 2018 to 2018
$225k
NHLBI NIH HHS R43 HL142418NHLBI NIH HHS R44 HL142418NIAID NIH HHS R43 AI129444NIAID NIH HHS R44 AI129444NIAID NIH HHS U01 AI138334
6 · The paper itself

Abstract

backgroundTherapeutic allogeneic mesenchymal stromal cells (MSCs) are currently in clinical trials to evaluate their effectiveness in treating many different disease indications. Eventual commercialization for broad distribution will require further improvements in manufacturing processes to economically manufacture MSCs at scales sufficient to satisfy projected demands. A key contributor to the present high cost of goods sold for MSC manufacturing is the need to create master cell banks from multiple donors, which leads to variability in large-scale manufacturing runs. Therefore, the availability of large single donor depots of primary MSCs would greatly benefit the cell therapy market by reducing costs associated with manufacturing.

methodsWe have discovered that an abundant population of cells possessing all the hallmarks of MSCs is tightly associated with the vertebral body (VB) bone matrix and only liberated by proteolytic digestion. Here we demonstrate that these vertebral bone-adherent (vBA) MSCs possess all the International Society of Cell and Gene Therapy-defined characteristics (e.g., plastic adherence, surface marker expression and trilineage differentiation) of MSCs, and we have therefore termed them vBA-MSCs to distinguish this population from loosely associated MSCs recovered through aspiration or rinsing of the bone marrow compartment.

resultsPilot banking and expansion were performed with vBA-MSCs obtained from 3 deceased donors, and it was demonstrated that bank sizes averaging 2.9 × 10 DISCUSSION: Thus, we have established a novel and plentiful source of MSCs that will benefit the cell therapy market by overcoming manufacturing and regulatory inefficiencies due to donor-to-donor variability.

Indexed as

AdolescentAdultAntigens, SurfaceBone Marrow CellsCell AdhesionCell Culture TechniquesCell DifferentiationCell LineageCell ProliferationCells, CulturedColony-Forming Units AssayFemaleHumansLymphocyte ActivationMaleMesenchymal Stem CellsAntigens, Surfacebone marrowcellular therapyhuman MSCslarge-scale manufacturingregenerative medicinevertebral bodies

Identifiers

PMID32873509
PMCPMC8919862
OpenAlexW3081778480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.